Recent Pfizer Press Releases

6/22/15 7:00am EDT
Pfizer Enters Into Agreement To Acquire Nimenrix And Mencevax From GlaxoSmithKline

Pfizer Inc. (NYSE: PFE) today announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million (€115 million).

6/11/15 3:00pm EDT
Pfizer Reports Top Line Results from a Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation in Pediatric Patients with Major Depressive Disorder

Pfizer Inc (NYSE: PFE) announced the top line results from a Phase 3 study which evaluated the efficacy, safety, and tolerability of Pristiq® (desvenlafaxine succinate sustained-release formulation) in pediatric patients ages 7 to 17 with Major Depressive Disorder (MDD).

6/10/15 8:00am EDT
Pfizer Builds Upon Robust Body Of Knowledge For XELJANZ® (tofacitinib citrate) With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress (EULAR 2015)

New Research on XELJANZ Monotherapy and Once-Daily Formulation Among Abstracts Accepted

Pfizer Inc. announced today that more than 20 abstracts including new rheumatoid arthritis (RA) research for XELJANZ® (tofacitinib citrate) will be presented at the European League Against Rheumatism Annual Congress (EULAR 2015) June 10-15, Rome, Italy.

6/8/15 11:00am EDT
Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology

Reinforces Pfizer’s Leadership in JAK Inhibition Research

Pfizer Inc. (NYSE:PFE) announced today that it has twelve presentations, including new research data on tofacitinib for chronic plaque psoriasis and atopic dermatitis, at the upcoming 23rd World Congress of Dermatology (WCD) meeting to be held on June 8-13 in Vancouver, Canada. 

6/4/15 9:00am EDT
Get Ready. Get Set. Get Old. Pfizer Challenges Conventional Views of Aging Through New Campaign

With more people living longer, Pfizer’s Get Old reminds us that ‘commencements’ can happen at any age

Pfizer is challenging Americans to embrace aging as not an end, but a beginning—a time to fulfill old dreams and make new ones a reality. For graduation season 2015, “Get Ready. Get Set.

5/30/15 7:30am EDT
Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

PALOMA-3 Data to Be Presented at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) and Published in The New England Journal of Medicine

Pfizer Inc.

5/29/15 8:30am EDT
Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE® (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system. This is the first approved treatment that helps stabilize lung function in patients with LAM.

5/28/15 8:30am EDT
Pfizer Announces $3 Million Grants Program to Further Clinical Research in Advanced Breast Cancer

Pfizer Inc. today announced the launch of a competitive, peer-reviewed grants program to support clinical research projects investigating IBRANCE® (palbociclib) in advanced breast cancer. The multi-year program, which will award a total of up to $3 million in grants to investigators in the United States, is an extension of Pfizer’s Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) initiative.

5/28/15 8:00am EDT
Pfizer Global Survey Finds Adults with Rheumatoid Arthritis Who Feel Comfortable Speaking Up About Their Concerns Have a More Positive View of Their Health

Healthcare professionals can “dig deeper” to help patients find satisfaction with disease management plans

Pfizer announced initial results of its global survey of more than 3,600 adults with rheumatoid arthritis (RA) in 13 countries. The RA NarRAtive patient survey is the first of its kind to simultaneously evaluate the patient and healthcare professional (HCP) relationship and communication, as well as the patient’s experience and satisfaction with treatment and disease management.

5/19/15 10:00am EDT
Pfizer Invites Public to View and Listen to Webcast of June 2 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Tuesday, June 2, 2015 at 4:30 p.m. EDT. The purpose of the call is to provide an update on Pfizer’s oncology business and to review Pfizer’s ASCO data presentations.

5/14/15 12:27pm EDT
Pfizer Receives Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira

Pfizer Inc. (NYSE:PFE) today announced that it has received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to its previously announced proposed acquisition of Hospira. The request for information from the FTC, often referred to as a “second request,” was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”).

5/14/15 8:07am EDT
Marc Tessier-Lavigne, Ph.D. to Leave Pfizer Board of Directors

Pfizer Inc. today announced that Director Marc Tessier-Lavigne, Ph.D. has decided to step down from its Board of Directors on May 14, 2015. His decision is coincident with the launch of Denali, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Dr. Tessier-Lavigne is a co-founder of Denali, and he will serve as the chairman of the company.

5/13/15 5:01pm EDT
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody

  • Early data demonstrates advances in the understanding of investigational immuno-oncology therapy avelumab across multiple tumor types
  • First presentations at a major global medical meeting since the formation of the alliance between Merck KGaA, Darmstadt, Germany and Pfizer


Merck KGaA, Darmstadt, Germany, and Pfizer today announced multiple presentations on studies evaluating the preliminary safety and efficacy of avelumab* at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.

5/11/15 4:30pm EDT
Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company

Option May Be Exercised Based on Phase II Trial Results for Recombinant Human Alkaline Phosphatase

AM‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, and Pfizer Inc. (NYSE:PFE) announced today that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company.

5/6/15 12:48pm EDT
Pfizer Appoints New Leaders for BioTherapeutics Research & Development and Rinat

Pfizer Inc. announced today two strategic appointments in the leadership of the Worldwide Research and Development organization effective immediately. Michael D. Ehlers, M.D., Ph.D., has been selected as Group Senior Vice President and Head of BioTherapeutics Research & Development and Site Head for Pfizer’s Cambridge and Boston, Massachusetts locations. 

4/28/15 7:00am EDT

Pfizer Inc. (NYSE:PFE) reported financial results for first-quarter 2015. The company manages its commercial operations through two distinct businesses: an Innovative Products business and an Established Products business.

4/23/15 2:07pm EDT
Pfizer Hosts Annual Meeting Of Shareholders

Declares 28-Cent Second-Quarter 2015 Dividend

The board of directors of Pfizer Inc. today declared a 28-cent second-quarter 2015 dividend on the company’s common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015. The second-quarter 2015 cash dividend will be the 306th consecutive quarterly dividend paid by Pfizer.

4/21/15 10:00am EDT
Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer

Pfizer Inc. announced today that XALKORI® (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC).

4/21/15 8:00am EDT
Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Pfizer today announced that the Phase 3 study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL) compared to that achieved with standard of care chemotherapy.

4/20/15 8:00am EDT
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

  • First of several registration trials expected to start in 2015 for the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer
  • Initiation and first patient treated in Phase III clinical study recruiting across approximately 290 sites in more than 30 countries
  • The primary endpoint of the study is overall survival (OS) in patients with programmed death-ligand 1 positive (PD-L1+) stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy


Merck KGaA, Darmstadt, Germany, and Pfizer Inc, New York, US, today announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior pl